Circulating Tumor DNA in Soft Tissue Sarcoma
Recruiting now NCT03818412
Run by University Health Network, Toronto · for 18 and older · All sexes
What this study is about
This research study will collect blood and tumor tissue samples from patients with soft tissue sarcoma to look at circulating tumor deoxyribonucleic acid (DNA). When tumor cells are damaged or die, DNA from the tumor cells are released into the blood stream as the cells break down. This is called circulating tumor DNA. Circulating tumor DNA is an important biomarker that may be used in cancer detection, prediction of treatment response, and disease monitoring.
Who can join (things the study team will check)
✅ You may be able to join if…
- Patients must have histologically confirmed high-risk extremity or retroperitoneal liposarcoma, leiomyosarcoma and undifferentiated pleomorphic sarcoma.
- Patients must have archival tissue from the diagnostic biopsy available.
- Deemed appropriate for preoperative or postoperative radiotherapy and curative surgery following patient assessment by radiation oncologist and surgical oncologist.
- Age 18 years or older.
- Eastern Cooperative Group (ECOG) performance status ≤ 2
- Ability to understand and willing to sign a written informed consent document and comply with study requirements.
🚫 You may not be able to join if…
- Patients with benign histology
- Patients with prior malignancy within previous 5 years or concurrent malignancy other than adequately treated basal cell carcinoma of skin or carcinoma in-situ of cervix.
- Patients with planned neo-adjuvant chemotherapy.
- Patients with regional nodal disease or unequivocal metastases
- Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Where this trial is running
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Who to contact
Albiruni Razak, M.D. · 416-946-2000 · albiruni.razak@uhn.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT03818412.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.